Baxdrostat met primary, secondary endpoints in BaxHTN Phase III trial in patients with… EP News Bureau Jul 24, 2025 Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor that targets the hormone driving…
AstraZeneca to buy US-based CinCor Pharma in $1.8 billion deal Reuters Jan 11, 2023 AstraZeneca said it will pay $26 per CinCor share in cash, a premium of nearly 121 per cent to the stock's closing price
